Harbor Capital Advisors, Inc. Magenta Therapeutics, Inc. Transaction History

Harbor Capital Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 11, 2023	BUY	$0.62 - $0.79 $9,495 - $12,099	15,316 Added 10.07%	167,454 $127,000
Q1 2023 Apr 26, 2023	SELL	$0.41 - $0.86 $3,597 - $7,545	-8,774 Reduced 5.45%	152,138 $120,000
Q4 2022 Jan 20, 2023	SELL	$0.36 - $1.59 $1,238 - $5,471	-3,441 Reduced 2.09%	160,912 $0
Q3 2022 Oct 28, 2022	BUY	$1.26 - $2.09 $6,357 - $10,546	5,046 Added 3.17%	164,353 $232,000
Q2 2022 Jul 26, 2022	BUY	$0.97 - $3.08 $7,476 - $23,740	7,708 Added 5.08%	159,307 $191,000
Q1 2022 Apr 28, 2022	SELL	$2.55 - $5.23 $76,831 - $157,579	-30,130 Reduced 16.58%	151,599 $440,000
Q4 2021 Feb 04, 2022	BUY	$4.43 - $8.33 $805,059 - $1.51 Million	181,729 New	181,729 $805,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.